J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in
J&J’s third-line multiple myeloma blockbuster Darzalex got the FDA green light for a new regimen to take another swing at the blood cancer — this time, in a cocktail with carfilzomib and dexamethasone.
The combination therapy was approved to treat relapsed or refractory multiple myeloma patients who have already received one to three lines of treatment.
Darzalex, a CD38-directed antibody, led the market for years after its approval in 2015 for third-line multiple myeloma patients. But this year, it faces competition from Sanofi’s Sarclisa, another CD38-targeting drug approved in April as a third-line treatment for multiple myeloma patients, in combination with pomalidomide and dexamethasone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.